Following news of disappointing study results of its lead cancer compound, Ceplene, and a 50 percent cut of its work force, San Diego-based biotechnology firm Maxim Pharmaceuticals announced last week that it pulled its application to seek marketing approval for the drug...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129